Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Ynvisible Interactive Inc. (TSXV: YNV) (FSE: 1XNA) (OTCQB: YNVYF) (the "Company" or "Ynvisible") is pleased to announce the appointment of Michael Kott as a new independent member of its Board of Directors, effective March 9, 2026.Michael Kott is the Founder & CEO of CM-Equity AG. Founded in 2002, he built the firm from a proprietary equity trading desk into a BaFin-regulated investment bank operating across Europe under MiFID II, before trans ...

Oslo, Norway, 09 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a collaboration with Etcembly Ltd, a biotechnology company applying advanced machine learning to T cell receptor (TCR) discovery and engineering. Highlights: AI-enabled collaboration to engineer KKLC1-targeting TCRs for Zelluna's TCR-NK platformBuilds on successful engineering of MAGE-A4 TCR underpi ...

biocare@icrhealthcare.comIndustry:- Technology- Health Technology- Medical Devices- Health- Oncology- Research- Software- Science### Agilent Technologies Inc.NYSE:ADetailsHeadquarters: Santa Clara, California, USAWebsite: www.agilent.comCEO: Padraig McDonnellEmployees: 18000Organization: PUB--- Release Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology SolutionsMar 9, 2026 3:00 AM Eastern Daylight Time# Agilent to Acquire Biocare Medical, a Global Leader in Clinical and R ...

ASML publishes agenda Annual General Meeting 2026Appointment and reappointment of Board of Management members and changes in Supervisory Board announced VELDHOVEN, the Netherlands, March 9, 2026 – Today, ASML Holding NV (ASML) has published the agenda for the 2025 Annual General Meeting (AGM) which will be held in ASML’s TWINSCAN Auditorium in Veldhoven on Wednesday, April 22, 2026, starting at 10:00 CET. The agenda with the explanatory notes and other meeting documents are available at www.asml.com/agm2026 ...

ENDEAVOUR REPORTS FATAL ACCIDENT AT MANA MINE London, 9 March 2026 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) (“Endeavour” or the “Company”) regrets to report that a contractor colleague passed away on 6 March 2026, as a result of injuries sustained in an incident that occurred during maintenance activities at the scrapyard at the Mana mine in Burkina Faso. Mining and processing activities remain uninterrupted while Endeavour conducts a comprehensive internal investigation into the incident. Th ...

Core Viewpoint - Rolls-Royce share price has entered a correction phase, dropping 11% from its year-to-date high of 1,420p to 1,295p, amid broader market sell-offs and geopolitical tensions in the Middle East [1][1][1] Group 1: Stock Performance - The stock price has retreated in line with the FTSE 100 Index, which fell from £10,930 on February 27 to £10,285 [1][1] - Analysts suggest a potential rebound to the year-to-date high of 1,500p, contingent on market conditions [1][1] Group 2: Business Impact - Rolls-Royce's revenue reached £20 billion last year, with operating profit increasing from £2.46 billion to £3.46 billion [1][1] - The company has initiated a £1 billion share buyback and resumed dividend payments for the first time in five years, aiming to distribute between £7 billion and £9 billion to shareholders from 2026 to 2028 [1][1][1] Group 3: Competitive Position - Rolls-Royce is becoming a significant player in the data center industry and is investing in small modular reactors (SMR) [1][1] - The company has a forward PE ratio of 33, lower than GE Aerospace's 43, and an EV-to-EBITDA of 21, compared to GE's 30, indicating a potentially favorable valuation [1][1] Group 4: Technical Analysis - The stock has shown a strong uptrend, moving from a low of 62p in 2022 to a high of 1,420p this year, currently trading at 1,265p [1][1] - The stock remains above the 100-day Exponential Moving Average and an ascending trendline, suggesting a bullish outlook despite recent volatility [1][1]

Kira Makagon, President and COO of RingCentral (RNG +6.18%), reported the sale of 22,196 shares of Common Stock for a transaction value of approximately $780,000 on Feb. 27, 2026, according to a SEC Form 4 filing.Transaction summaryMetricValueShares sold (direct)22,196Transaction value$780,278.91Post-transaction shares (direct)339,545Post-transaction value (direct ownership)~$12.38 millionTransaction value based on SEC Form 4 weighted average purchase price ($35.15); post-transaction value based on Feb. 27, ...

Core Insights - The combination of Roche's investigational drug giredestrant with Pfizer's Ibrance did not result in a statistically significant improvement for patients with advanced breast cancer [1] Company Analysis - Roche's investigational drug giredestrant was tested in combination with Pfizer's Ibrance for treating advanced breast cancer [1] - The study results indicate that the combination therapy did not meet the expected efficacy benchmarks [1] Industry Implications - The lack of statistically significant improvement in treatment outcomes may impact future research and development strategies within the oncology sector [1] - This outcome could influence investor sentiment and market dynamics for both Roche and Pfizer in the competitive landscape of breast cancer therapies [1]

Core Viewpoint - The company, Electromagnetic Geoservices ASA (EMGS), is pursuing a transaction to transfer its business operations and assets to an undisclosed buyer as part of a strategic review to safeguard stakeholder interests [2][5]. Group 1: Transaction Details - EMGS has signed a non-binding term sheet with a third-party buyer for the acquisition of its business operations, including hardware, intellectual property rights, contractual positions, and all employees [2]. - The transaction structure involves transferring the EM Business to a subsidiary (NewCo) before ownership is transferred to the buyer [3]. - The purchase price for the EM Business is expected to be significantly below the outstanding debt under the convertible bond issue EMGS03, indicating that EMGS will not retain substantial assets post-transaction [4]. Group 2: Strategic Review and Alternatives - The strategic review conducted by EMGS over several months concluded that the transaction represents the best available alternative to protect the interests of stakeholders, as other options like restructuring or winding down operations were deemed unviable [5]. - The buyer will commence a due diligence review of the EM Business, although there are no guarantees that a binding agreement will be reached or that the transaction will be completed [6]. Group 3: Operational Context - EMGS is a leader in the marine electromagnetic market, utilizing proprietary technology to assist oil and gas companies in offshore hydrocarbon exploration, enhancing efficiency and reducing costs [8].

Core Viewpoint - GenSight Biologics is advancing its gene therapy candidate GS010/LUMEVOQ® for retinal neurodegenerative diseases and central nervous system disorders, with updates on early access programs and a dose-ranging study [1] Group 1: Company Updates - GenSight Biologics provided updates on the GS010/LUMEVOQ® early access programs currently underway [1] - The company is conducting an ongoing dose-ranging study named REVISE for GS010/LUMEVOQ® [1] - GS010/LUMEVOQ® is positioned as a candidate gene therapy in clinical development [1]